4basebio Valuation Multiples

Discover revenue and EBITDA valuation multiples for 4basebio and similar public comparables like Bioventix, ArcticZymes, SDI Group, Curiosis and more.

4basebio Overview

About 4basebio

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.


Founded

2019

HQ

United Kingdom

Employees

110

Financials (LTM)

Revenue: $3M
EBITDA: ($21M)

EV

$108M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

4basebio Financials

4basebio reported last 12-month revenue of $3M and negative EBITDA of ($21M).

In the same LTM period, 4basebio generated $2M in gross profit, ($21M) in EBITDA losses, and had net loss of ($22M).


4basebio P&L

In the most recent fiscal year, 4basebio reported revenue of $2M and EBITDA of ($21M).

4basebio is unprofitable as of last fiscal year, with gross margin of 58%, EBITDA margin of (920%), and net margin of (997%).

See analyst estimates for 4basebio
LTMLast FY202320242025202620272028
Revenue$3M$2M$681K$1M$2M
Gross Profit$2M$1M$457K$847K$1M
Gross Margin62%58%67%68%58%
EBITDA($21M)($21M)($10M)($15M)($21M)
EBITDA Margin(674%)(920%)(1451%)(1176%)(920%)
EBIT Margin(731%)(984%)(1614%)(1371%)(984%)
Net Profit($22M)($23M)($10M)($17M)($23M)
Net Margin(718%)(997%)(1515%)(1322%)(999%)

Financial data powered by Morningstar, Inc.

4basebio Stock Performance

4basebio has current market cap of $109M, and enterprise value of $108M.

Market Cap Evolution


4basebio's stock price is $7.06.

4basebio share price increased by 2.5% in the last 30 days, and decreased by 45.5% in the last year.

4basebio has an EPS (earnings per share) of $-1.47.

See more trading valuation data for 4basebio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$108M$109M-0.2%2.5%3.7%-45.5%$-1.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

4basebio Valuation Multiples

4basebio trades at 34.9x EV/Revenue multiple, and (5.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for 4basebio

4basebio Financial Valuation Multiples

As of July 19, 2026, 4basebio has market cap of $109M and EV of $108M.

4basebio has a P/E ratio of (4.9x).

LTMLast FY202320242025202620272028
EV/Revenue34.9x47.4x158.5x86.0x47.4x
EV/EBITDA(5.2x)(5.2x)(10.9x)(7.3x)(5.2x)
EV/EBIT(4.8x)(4.8x)(9.8x)(6.3x)(4.8x)
EV/Gross Profit55.9x82.4x235.9x127.3x82.4x
P/E(4.9x)(4.8x)(10.6x)(6.6x)(4.8x)
EV/FCF(5.0x)(4.8x)(10.5x)(6.5x)(4.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified 4basebio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

4basebio Margins & Growth Rates

4basebio grew revenue by 65% but EBITDA decreased by 6% in the last fiscal year.

In the most recent fiscal year, 4basebio reported gross margin of 58%, EBITDA margin of (920%), and net margin of (997%).

See estimated margins and future growth rates for 4basebio

4basebio Margins

Last FY202420252026202720282029
Gross Margin58%68%58%64%
EBITDA Margin(920%)(1176%)(920%)(521%)
EBIT Margin(984%)(1371%)(984%)(573%)
Net Margin(997%)(1322%)(999%)(579%)
FCF Margin(997%)(1320%)(1018%)(557%)

4basebio Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth65%84%81%65%
Gross Profit Growth85%85%55%85%
EBITDA Growth(6%)49%42%(6%)
EBIT Growth(4%)57%30%(4%)
Net Profit Growth(4%)61%37%(4%)
FCF Growth(8%)61%40%(9%)

Data powered by FactSet, Inc. and Morningstar, Inc.

4basebio Operational KPIs

4basebio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

4basebio's Rule of 40 is (456%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

4basebio's Rule of X is (358%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for 4basebio
LTMLast FY202320242025202620272028
Rule of 40(433%)(456%)---
Bessemer Rule of X(72%)(358%)---
Revenue per Employee-$0.0M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue-48%55%38%48%
G&A Expenses to Revenue-85%249%151%85%
R&D Expenses to Revenue-303%704%502%303%
Opex to Revenue-1042%1681%1439%1042%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

4basebio Competitors

4basebio competitors include Bioventix, ArcticZymes, SDI Group, Curiosis, HAEMATO, Vitrafy, Jagsonpal Pharma, Insight Molecular, Diaceutics and iNtRON Biotechnology.

Most 4basebio public comparables operate across Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Bioventix5.8x-7.4x-
ArcticZymes6.1x5.6x33.5x38.3x
SDI Group1.8x1.5x9.7x8.0x
Curiosis26.7x16.2x(29.3x)(64.4x)
HAEMATO0.2x-3.1x-
Vitrafy2932.0x93.1x(15.0x)(10.9x)
Jagsonpal Pharma4.8x-20.3x-
Insight Molecular31.5x42.5x(4.9x)(4.6x)

This data is available for Pro users. Sign up to see all 4basebio competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About 4basebio

When was 4basebio founded?4basebio was founded in 2019.
Where is 4basebio headquartered?4basebio is headquartered in United Kingdom.
How many employees does 4basebio have?As of today, 4basebio has over 110 employees.
Who is the CEO of 4basebio?4basebio's CEO is Amy Jo Walker.
Is 4basebio publicly listed?Yes, 4basebio is a public company listed on London Stock Exchange.
What is the stock symbol of 4basebio?4basebio trades under 4BB ticker.
When did 4basebio go public?4basebio went public in 2021.
Who are competitors of 4basebio?4basebio main competitors include Bioventix, ArcticZymes, SDI Group, Curiosis, HAEMATO, Vitrafy, Jagsonpal Pharma, Insight Molecular, Diaceutics, iNtRON Biotechnology.
What is the current market cap of 4basebio?4basebio's current market cap is $109M.
What is the current revenue of 4basebio?4basebio's last 12 months revenue is $3M.
What is the current revenue growth of 4basebio?4basebio revenue growth (NTM/LTM) is 241%.
What is the current EV/Revenue multiple of 4basebio?Current revenue multiple of 4basebio is 34.9x.
Is 4basebio profitable?No, 4basebio is not profitable.
What is the current EBITDA of 4basebio?4basebio has negative EBITDA and is not profitable.
What is 4basebio's EBITDA margin?4basebio's last 12 months EBITDA margin is (674%).
What is the current EV/EBITDA multiple of 4basebio?Current EBITDA multiple of 4basebio is (5.2x).
What is the current FCF of 4basebio?4basebio's last 12 months FCF is ($22M).
What is 4basebio's FCF margin?4basebio's last 12 months FCF margin is (704%).
What is the current EV/FCF multiple of 4basebio?Current FCF multiple of 4basebio is (5.0x).
How many companies 4basebio has acquired to date?4basebio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies 4basebio has invested to date?4basebio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to 4basebio

Lists including 4basebio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial